<DOC>
	<DOCNO>NCT00586131</DOCNO>
	<brief_summary>This study test hypothesis slightly lower acidity blood ( increase pH ) , dialysis patient utilize protein amino acid efficiently .</brief_summary>
	<brief_title>Arterial pH N-balances APD</brief_title>
	<detailed_description>The normal range pH blood ( measure acid-base balance body ) rather large . It define range pH 7.38 7.44 . There evidence suggest high normal arterial pH ( 7.43-7.45 ) preserve nutritional status individual well low normal arterial pH ( 7.36-7.38 ) . We test hypothesis small group stable patient end-stage renal disease undergo automate peritoneal dialysis . It need noted pH level attain study consider normal . The primary outcome measure study N-balance . The change blood pH obtain medication ( ammonium chloride low pH sodium bicarbonate high pH ) . Study Procedures : A total eight subject end-stage renal disease undergo automate peritoneal dialysis recruit . The initial study procedure purpose screen individual study . The subject perform 24-hour collection urine dialysate assess dialysis dose peritoneal equilibration test evaluate transport property peritoneum . Only subject receive minimum dialysis dose average peritoneal transport type enter study . During phase , subject maintain food diary evaluate dietary preference dietary calorie protein intake . These data use prepare diet subject admit GCRC . The next two week use evaluate response arterial pH use low alkali solution . If , end two week , arterial pH desire range , subject require ammonium chloride supplementation achieve low pH . In subject , ammonium chloride supplementation use phase study . Qualifying subject hospitalize GCRC 41 day . The entire period hospitalization divide two equal phase 20.5 day : one low pH phase ( low alkali dialysis solution with/without ammonium chloride ) second high pH phase ( high alkali dialysis solution sodium bicarbonate with/without ammonium chloride ) . Nitrogen balance estimate entire period hospitalization . N-intake sum dietary medicinal intake , N-output N-losses dialysate , urine feces . The N-balance difference N-intake N-output . The second outcome measure leucine turnover study . Leucine turnover study perform day 21 41 . Leucine turnover study provide information regard rate total body protein synthesis total body protein degradation well rate leucine oxidation . The study take 10 hour - initial 4 hour overnight fast last six hour feed . The third outcome measure content proteins sample muscle biopsy . Muscle biopsy perform day 21 41 completion leucine turnover study . Finally , nutritional assessment perform time patient admission , day 21 41 . On day 21 41 , nutritional assessment perform prior start leucine turnover study . The subject compensate participation study -the amount compensation dependent upon degree participation subject . Risk-benefit Assessment : The risk study include risk perform muscle biopsy , discomfort associate placement feed tube , emotional problem associate prolonged hospitalization GCRC risk associated venipuncture . There direct benefit subject result participation study . However , demonstrate high arterial pH well preservation nutritional status , may potential decrease prevalence and/or severity protein-energy malnutrition patient undergo automated peritoneal dialysis .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Citric Acid</mesh_term>
	<criteria>1 . Men woman ethnic/racial group &lt; 65 year . 2 . Treatment CPD 6 month current treatment APD least one month . 3 . Hemoglobin least 11.0 g/dl . 4 . Stable dose erythropoietin treatment least precede three month . 5 . Subjects normal nutritional status mild malnutrition : 1 . Serum albumin &gt; 3.3 g/dl 2 . Relative body weight 90120 % NHANES II median body weight give height , age range , gender frame size . 3 . A normalized protein equivalent total nitrogen appearance ( nPNA ) &gt; 0.80 g/kg actual body weight/day time screen . 6 . D/P Cr 0.48 0.81 PET perform time screen . 7 . Total ( renal + peritoneal ) weekly Kt/V urea &gt; 1.70 creatinine clearance &gt; 50 L/wk/1.73 m2 . 8 . No evidence primary secondary ( viz. , ischemic , neuropathic ) myopathy 1 . History active cancer basal cell carcinoma . 2 . Symptomatic severe ischemic heart disease , uncontrolled severe dysrhythmias , uncontrolled congestive heart failure , poorly control hypertension , severe musculoskeletal disease , arthritis amputation low extremity . 3 . Insulin require diabetes mellitus . 4 . Patients receive Lcarnitine anabolic hormone ( erythropoietin ) within previous 6 month . 5 . Use CaCO3 phosphate binder . 6 . Severe lung liver disease , uncontrolled asthma , active vasculitis . 7 . Severe chronic infection acute chronic inflammatory catabolic illness ( e.g. , active tuberculosis , AIDS , osteomyelitis ) . 8 . Psychosis , inability give inform consent , evidence patient comply study protocol . 9 . Alcohol recreational drug abuse . 10 . Pregnancy ( rare CPD patient ) . 11 . Patients physically and/or psychologically incapable undergoing protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>end-stage renal disease</keyword>
	<keyword>automate peritoneal dialysis</keyword>
	<keyword>metabolic acidosis</keyword>
	<keyword>nitrogen balance</keyword>
</DOC>